Mutation Associated with increased Cancer Risk Therapeutic Indication Germline Test for metastatic PCa Germline Test for metastatic PCa Germline Test for metastatic PCa
Mutation Rate in European descendant (%) Mutation Rate in African descendant (%) Reference
BRCA 1
x
PARPi
0.5% 0.77% 0.87% 2.0% 0.0% 0.0% Ledet et al.64 Na et al.70 Pritchard et al.65
BRCA 2
x
PARPi
5.0% 3.07% 4.77% 5.10% 4.0% 0.0% 0.0% 0.90% Ledet et al.64 Na et al.70 Pritchard et al.65 Plym et al.71
ATM
x
PARPi
1.0% 1.53% 1.01% 0.0% 3.33% 0.14% Ledet et al.64 Na et al.70 Pritchard et al.65
PALB2
x
0.50% 0.43% 0.50% 0.0% Ledet et al.64 Pritchard et al.65
CHECK2
x
PARPi
2% 1.01% 0.0% 0.0% Ledet et al.64 Pritchard et al.65
MSH2
x
Checkpoint Inhibitor
0.20% 0.14% 0.70% 0.0% 0.0% 1.80% Ledet et al.64 Pritchard et al.65 Plym et al.71
MSH6
x
Checkpoint Inhibitor
0.50% 0.14% 0.30% 0.50% 0.0% 0.00% Ledet et al.64 Pritchard et al.65 Plym et al.71
PMS2
x
Checkpoint Inhibitor
0.30% 0.70% 0.50% 0.00% Ledet et al.64 Plym et al.71
FANCA x PARPi 0.30% 0.00% Plym et al.71
NBN
x
PARPi
1% 0.14% 0.00% 0.0% 0.0% 0.90% Ledet et al.64 Pritchard et al.65 Plym et al.71